✓ Translated by DotMD AI Clinical Council Source: Hypertension research : official journal of the Japanese Society of Hypertension • Randomized Controlled Trial

Verify Primary Source: NIH PubMed PMID #30552406 ↗

Randomized Controlled Trial: Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension

Original Paper Title: “Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Randomized Controlled Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Telmisartan interacted with rosuvastatin on reducing WMH progression and cognitive function decline. Findings suggest that low-dose rosuvastatin could reduce WMH progression and cognitive function decline in antihypertensive patients, as demonstrated by the interaction between telmisartan and low-dose rosuvastatin to this effect.
Study Design & Sample: Randomized Controlled Trial published in Hypertension research : official journal of the Japanese Society of Hypertension (Multi-cohort synthesis).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Hypertension research : official journal of the Japanese Society of Hypertension (2019), this randomized controlled trial evaluating human clinical outcomes investigated: Cerebral white matter hyperintensities (WMHs) and cognitive impairment are common in elderly hypertensive patients, and more needs to be learned about their prevention and treatment. Key clinical takeaway: Telmisartan interacted with rosuvastatin on reducing WMH progression and cognitive function decline. Findings suggest that low-dose rosuvastatin could reduce WMH progression and cognitive function decline in antihypertensive patients, as demonstrated by the interaction between...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Hypertension research : official journal of the Japanese Society of Hypertension, 2019-05-15; Randomized Controlled Trial; Rigor 88/100): Telmisartan interacted with rosuvastatin on reducing WMH progression and cognitive function decline. Findings suggest that low-dose rosuvastatin could reduce WMH progression and cognitive function decline in antihypertensive patients, as demonstrated by the interaction between telmisartan and low-dose rosuvastatin to this effect.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: low-dose-naltrexone → Rx: oral-minoxidil → Rx: angiotensin-ii → Rx: rosuvastatin-calcium → Condition: aortic-aneurysm-of-unspecified-site-ruptured → Condition: aortic-aneurysm-of-unspecified-site-without-rupture →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 30552406: Randomized Controlled Trial: Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension

3 of 3 Free Questions Remaining